These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 32789284)

  • 1. Occlusive Retinal Vasculitis Following Intravitreal Brolucizumab.
    Witkin AJ; Hahn P; Murray TG; Arevalo JF; Blinder KJ; Choudhry N; Emerson GG; Goldberg RA; Kim SJ; Pearlman J; Schneider EW; Tabandeh H; Wong RW
    J Vitreoretin Dis; 2020 Jul; 4(4):269-279. PubMed ID: 32789284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.
    Monés J; Srivastava SK; Jaffe GJ; Tadayoni R; Albini TA; Kaiser PK; Holz FG; Korobelnik JF; Kim IK; Pruente C; Murray TG; Heier JS
    Ophthalmology; 2021 Jul; 128(7):1050-1059. PubMed ID: 33207259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brolucizumab-associated intraocular inflammation in eyes without retinal vasculitis.
    Witkin AJ; Hahn P; Murray TG; Arevalo JF; Blinder KJ; Choudhry N; Emerson GG; Goldberg RA; Kim SJ; Pearlman J; Schneider EW; Tabandeh H; Wong RW
    J Vitreoretin Dis; 2021 Jul; 5(4):326-332. PubMed ID: 34604691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab.
    Baumal CR; Spaide RF; Vajzovic L; Freund KB; Walter SD; John V; Rich R; Chaudhry N; Lakhanpal RR; Oellers PR; Leveque TK; Rutledge BK; Chittum M; Bacci T; Enriquez AB; Sund NJ; Subong ENP; Albini TA
    Ophthalmology; 2020 Oct; 127(10):1345-1359. PubMed ID: 32344075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retinal Vasculitis After Intravitreal Pegcetacoplan: Report From the ASRS Research and Safety in Therapeutics (ReST) Committee.
    Witkin AJ; Jaffe GJ; Srivastava SK; Davis JL; Kim JE
    J Vitreoretin Dis; 2024; 8(1):9-20. PubMed ID: 38223782
    [No Abstract]   [Full Text] [Related]  

  • 6. Detection and Management of Intraocular Inflammation after Brolucizumab Treatment for Neovascular Age-Related Macular Degeneration.
    Bodaghi B; Souied EH; Tadayoni R; Weber M; Ponthieux A; Kodjikian L
    Ophthalmol Retina; 2023 Oct; 7(10):879-891. PubMed ID: 37343623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration.
    Haug SJ; Hien DL; Uludag G; Ngoc TTT; Lajevardi S; Halim MS; Sepah YJ; Do DV; Khanani AM
    Am J Ophthalmol Case Rep; 2020 Jun; 18():100680. PubMed ID: 32258827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-Term Safety and Efficacy of Intravitreal Brolucizumab Injections for Neovascular Age-Related Macular Degeneration: A Multicenter Retrospective Real-World Study.
    Kim DJ; Jin KW; Han JM; Lee SH; Park YS; Lee JY; Lee EK; Lee JS; Kim ST; Shin MH; Lee CS; Jung HH; Jang JY; Kim M; Kim YH; Kim JH; Park KH; Park SJ; Joo K; Ji YS; Sagong M; Woo SJ
    Ophthalmologica; 2023; 246(3-4):192-202. PubMed ID: 36720210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expert Opinion on Management of Intraocular Inflammation, Retinal Vasculitis, and Vascular Occlusion after Brolucizumab Treatment.
    Baumal CR; Bodaghi B; Singer M; Tanzer DJ; Seres A; Joshi MR; Feltgen N; Gale R
    Ophthalmol Retina; 2021 Jun; 5(6):519-527. PubMed ID: 33007521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Frequency and Management of Ocular Adverse Events in Eyes with Neovascular Age-Related Macular Degeneration Treated with Brolucizumab.
    Zubricky R; McCoy J; Donkor R; Miller DG; Sonbolian N; Heaney A; Bilano V; Karcher H; Coney JM
    Ophthalmol Ther; 2023 Oct; 12(5):2397-2408. PubMed ID: 37310683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. INCIDENCE AND RISK FACTORS OF INTRAOCULAR INFLAMMATION AFTER BROLUCIZUMAB TREATMENT IN JAPAN: A Multicenter Age-Related Macular Degeneration Study.
    Inoda S; Takahashi H; Maruyama-Inoue M; Ikeda S; Sekiryu T; Itagaki K; Matsumoto H; Mukai R; Nagai Y; Ohnaka M; Kusuhara S; Miki A; Okada AA; Nakayama M; Nishiguchi KM; Takeuchi J; Mori R; Tanaka K; Honda S; Kohno T; Koizumi H; Miyara Y; Inoue Y; Takana H; Iida T; Maruko I; Hayashi A; Ueda-Consolvo T; Yanagi Y
    Retina; 2024 Apr; 44(4):714-722. PubMed ID: 38016089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three cases of brolucizumab-associated retinal vasculitis treated with systemic and local steroid therapy.
    Kataoka K; Horiguchi E; Kawano K; Ushida H; Nakano Y; Ito Y; Terasaki H
    Jpn J Ophthalmol; 2021 Mar; 65(2):199-207. PubMed ID: 33543352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations.
    Jain A; Chea S; Matsumiya W; Halim MS; Yaşar Ç; Kuang G; Sepah YJ; Khanani AM; Do DV; Nguyen QD
    Am J Ophthalmol Case Rep; 2020 Jun; 18():100687. PubMed ID: 32280811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Safety Outcomes with Brolucizumab in Neovascular Age-Related Macular Degeneration: Findings from the IRIS® Registry.
    Zarbin MA; MacCumber MW; Karcher H; Adiguzel E; Mayhook A; LaPrise A; Bilano VL; Igwe F; Ip MS; Wykoff CC
    Ophthalmol Ther; 2024 May; 13(5):1357-1368. PubMed ID: 38520643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinal arterial occlusive vasculitis after multiple intravitreal brolucizumab injections for diabetic macular edema.
    Hirano T; Toriyama Y; Takahashi Y; Hoshiyama K; Murata T
    Am J Ophthalmol Case Rep; 2023 Mar; 29():101788. PubMed ID: 36632338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Review of Real-World Evidence.
    Wykoff CC; Matsumoto H; Barakat MR; Karcher H; Lozama A; Mayhook A; Oshagbemi OA; Zorina O; Hassan TS; Khanani AM; Heier JS
    Retina; 2023 Jul; 43(7):1051-1063. PubMed ID: 36893438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocular adverse events following intravitreal brolucizumab for neovascular age-related macular degeneration at a single tertiary care center.
    Nguyen HV; Li AS; Silva AR; Leng T
    Eur J Ophthalmol; 2022 Sep; 32(5):2747-2751. PubMed ID: 34761684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vancomycin-Associated Hemorrhagic Occlusive Retinal Vasculitis: Clinical Characteristics of 36 Eyes.
    Witkin AJ; Chang DF; Jumper JM; Charles S; Eliott D; Hoffman RS; Mamalis N; Miller KM; Wykoff CC
    Ophthalmology; 2017 May; 124(5):583-595. PubMed ID: 28110950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. INTRAOCULAR INFLAMMATION INCIDENCE AFTER INTRAVITREAL BROLUCIZUMAB INJECTION FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
    Pakravan P; Patel V; Lai J; Shaheen A; Kalahasty K; Reyes-Capo DP; Chau V; Rosenfeld PJ; Haddock LJ; Schwartz SG; Smiddy WE; Kovach JL; Sridhar J; Flynn HW; Albini TA; Yannuzzi NA
    Retina; 2023 Oct; 43(10):1717-1722. PubMed ID: 37320859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A CONSENSUS ON RISK MITIGATION FOR BROLUCIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Patient Selection, Evaluation, and Treatment.
    Holz FG; Iida T; Maruko I; Sadda SR
    Retina; 2022 Sep; 42(9):1629-1637. PubMed ID: 35994582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.